Novartis (NVS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

CYP17A1 Inhibitors Market to Reach USD 1.35 Billion by 2025, Fueled by Advancements in Prostate Cancer Therapeutics The CYP17A1 inhibitors market is projected to attain USD 1,350 million by 2025, ...

Cosentyx missed its main goal in a Phase 3 GCA study, but showed lower steroid use. Novartis plans full review of the trial ...

What’s powering a $26.28 billion opportunity? The global ophthalmology drugs market, valued at US$18.34 billion in 2024 stood ...

Switzerland is a major exporter of drugs to the U.S., with pharmaceuticals accounting for almost half of Swiss goods exports to America in 2024.

Novartis AG’s drug Cosentyx failed in a late-stage study of patients suffering from inflammation in their blood vessels, a ...

The GCAptAIN study did not meet its primary endpoint of sustained remission at Week 52 in adults with newly diagnosed or relapsing GCA1 ...

LONDON, GREATER LONDON, UNITED KINGDOM, July 7, 2025 /EINPresswire.com/ -- Save 30% On All Global Market Reports With Code ONLINE30 – Stay Informed On Tariff Changes, Macroeconomic Trends, And More.

In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Buy rating on Novartis AG, with a price target of CHF115.00. The company’s shares opened today at CHF96.53. Papadakis ...

The Alzheimer’s Drugs Market is anticipated to experience a compound annual growth rate (CAGR) of approximately 20% over the ...

See the latest Novartis AG Registered Shares stock price (NOVN:XSWX), related news, valuation, dividends and more to help you make your investing decisions.

See the latest Novartis AG ADR stock price (NVS:XNYS), related news, valuation, dividends and more to help you make your investing decisions.